Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Research ArticleOriginal Article
Open Access

Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients

Haider H. Zalzala, Galawish A. Abdullah, Mohammed Y. Abbas, Hyam R. Mohammedsalih and Batool M. Mahdi
Saudi Medical Journal September 2018, 39 (9) 886-890; DOI: https://doi.org/10.15537/smj.2018.9.23156
Haider H. Zalzala
From the HLA Typing Research Unit (Zalzala, Mohammedsalih, Mahdi), College of Medicine, and from the Department of Medicine (Abdullah, Yaseen), Al-kindy College of Medicine, University of Baghdad, Baghdad, Iraq
MBChB, FICMS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Galawish A. Abdullah
From the HLA Typing Research Unit (Zalzala, Mohammedsalih, Mahdi), College of Medicine, and from the Department of Medicine (Abdullah, Yaseen), Al-kindy College of Medicine, University of Baghdad, Baghdad, Iraq
MBChB, FICMS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed Y. Abbas
From the HLA Typing Research Unit (Zalzala, Mohammedsalih, Mahdi), College of Medicine, and from the Department of Medicine (Abdullah, Yaseen), Al-kindy College of Medicine, University of Baghdad, Baghdad, Iraq
MBChB, FICMS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyam R. Mohammedsalih
From the HLA Typing Research Unit (Zalzala, Mohammedsalih, Mahdi), College of Medicine, and from the Department of Medicine (Abdullah, Yaseen), Al-kindy College of Medicine, University of Baghdad, Baghdad, Iraq
MBChB, MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Batool M. Mahdi
From the HLA Typing Research Unit (Zalzala, Mohammedsalih, Mahdi), College of Medicine, and from the Department of Medicine (Abdullah, Yaseen), Al-kindy College of Medicine, University of Baghdad, Baghdad, Iraq
MBChB, FICMS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

Objectives: To investigate the role of Human leukocyte antigen (HLA) Class II DRB1 in susceptibility to psoriasis in Iraqi patients.

Methods: A cross-sectional comparative study including 40 patients with psoriasis attending the Department of Dermatology, Al-Kindy teaching hospital in Baghdad, Iraq, between September 2013-2015. Patient selection was carried out by the dermatologists. Ninety healthy individuals were included in the study. Human leukocyte antigen genotyping was carried out by the sequence specific oligonucleotide (SSO) method using Auto LiPA 48 (Innogenetics, Belgium) in the HLA typing research unit of the Al-Kindy College of Medicine, Baghdad, Iraq.

Results: There is an increased frequency of HLA-DRB1*0102, *0306 in psoriatic patients with psoriasis p-values=0.001, confidence interval(CI)=2.492-37.487 and odds ratio(OR)=9.666. Human leukocyte antigen-DRB1*1101 is significantly associated with plaque-type psoriasis with p=0.0434, CI=1.04-1.69, and OR=4.2. Human leukocyte antigen-DRB1*0102 is significantly associated with other types of psoriasis with p=0.018, CI=0.0223-0.701, and OR=0.125.

Conclusion: Human leukocyte antigen-DRB1*0102 and *0306 are significantly associated with psoriasis. Human leukocyte antigen-DRB1*1101 is significantly associated with plaque-type psoriasis. Human leukocyte antigen-DRB1*0102 is significantly associated with other types of psoriasis rather than plaque-type psoriasis.

Psoriasis is a chronic inflammatory skin disorder affecting 1% of the population worldwide, which is clinically characterized by erythematous, sharply demarcated papules and rounded plaques, covered by silvery micaceous scales.1 It can involve the skin, scalp, nails, and joints. Psoriasis has a bimodal age distribution. In one group, onset typically occurs around 30 years of age, often in individuals with positive family history and severe course of the disease. In the other group, onset occurs around 50-60 years of age, usually with a less severe course and without family history. There is no gender predominance.2 There are many types of psoriasis, (plaque-type, inverse, guttetate, and pustular), with the plaque-type being the most common. Up to 30% of patients with psoriasis have psoriatic arthritis.1

The etiology of psoriasis is not truly understood, but genetic, immune pathological and environmental factors may be involved in its pathogenesis. Children have a 15% chance of having psoriasis if one parent is affected and a 50% chance if both parents are affected.2,3

Psoriatic lesions have been shown to be infiltrated with activated T-cells which is responsible for keratinocyte hyperproliferation through cytokine production. Recently, it has been suggested that there are 2 newly discovered antigens playing a role in psoriasis pathogenesis. The first is cathelicidin (LL37), derived from keratinocyte and may be considered as an autoantigen since it is an antimicrobial peptide. The second antigen is ADAMTS-like protein 5 (ADAMTSL5), which is originated from melanocytes and acts as an antigen for interleukin(IL)-17-production from T-cells.4,5 These antigens are presented to T-cells by HLAs, suggesting that HLA has a role in the pathogenesis of psoriasis.6,7 The bimodal age distribution of psoriasis indicates the existence of 2 pathogenically distinct forms of the disease, similar to the model of diabetes. Thus, severe type I is, strongly HLA-associated (particularly, HLA-C:06:02), in contrast to mild Type II which is HLA-unrelated.3,8,9

Several studies have reported an increased frequencies of the occurrence of HLA-class I (HLA-A1, A2, B13, B37, B39, B57, Cw1, Cw6) in patients with psoriasis.10 In addition, psoriatic arthritis has been associated with HLA-B57, although some studies have also reported HLA-Cw6 in more than 50% of all patients with this disease.11

The aim of this study was to investigate the role of HLA Class II DRB1 in susceptibility to psoriasis vulgaris and other forms of psoriasis in Iraqi patients and to contribute to the data related to HLA and psoriasis.

Methods

This is a cross-sectional comparative study carried out through direct interviews with patients attending the Department of Dermatology of the Al-Kindy teaching hospital in Baghdad, Iraq, between September 2013-2015. Inclusion criteria necessitated that all patients have previously or newly diagnosed of psoriasis vulgaris or any other types of psoriasis, included nail, scalp, palmoplantar, flexural, and pustular types.

The sample size was 130 subjects, 40 patients with psoriasis and 90 gender and age matched healthy control groups volunteers among the staff of Al-Kindey College of Medicine, Baghdad, Iraq, who did not have a history of psoriasis. The Sample size was calculated using Epi-tools Epidemiological calculator with a 0.95 confidence level.

Informed written consent was given to the patients. Ethical approval was obtained from the scientific unit of Al-Kindy College Of Medicine, Baghdad, Iraq, and the study was carried out in accordance with Helsinki Declaration.

HLA genotyping

Three milliliter venous blood was drawn by venipuncture from both the patients and control groups and kept at -20°C in an ethylenediamine tetraacetic acid (EDTA) containing tubes until DNA extraction which was carried out by using Qiagen DNA extraction Kit. Polymerase chain reaction (PCR), and SSO technique were used for HLA-DRB1 typing using both amplification and hybridization kits with Auto LiPA 48 automated machine from (Innogenitics, Belgium) according to manufacturer instructions. LIRAS version 5.0 software (Innogenetics, Belgium) was used for results interpretation.

Statistical analysis

Data was introduced in MiniTab version 15 software (Minitab Inc., State College, PA, USA). Frequency distribution tables were used to describe number and percentage of statistical variables. Chi square test was used to find out the association between related variables and Fishers exact test when needed. Odds ratio (OR) 95% confidence interval was calculated. A p-value<0.05 was considered significant.

Results

Forty Iraqi arab Muslim patients with psoriasis were included in the study. Ten of the 40 patients had a family history of psoriasis. The age of the patients ranged from 12-52 years old, with 18 males and 22 females.

Patients with psoriasis were divided into 2 groups: plaque-type and other types of psoriasis as shown in Table 1. Other types of psoriasis included nail, scalp, palmoplantar, flexural, and pustular types.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1

Number of patients according to psoriasis type.

The frequencies for significantly elevated HLA-DRB1 alleles identified by PCR-SSO in 40 patients with psoriasis compared to controls are shown in Table 2. Human leukocyte antigen-DRB1*0102 and *0306 were the most common allele frequencies in patients with psoriasis as compared to the healthy control group. In contrast, HLA-DRB1*0701, *0802, *1101, and *1401 showed no significant association with plaque psoriasis, while other HLA-DRB1 alleles that were tested failed to show any statistically significant association.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2

Human leukocyte antigen (HLA-DRB1*) allele frequencies, Odds ratio, confidence interval and p-value in patients with psoriasis and healthy controls.

Table 3 shows that the most common allele associated with plaque psoriasis as compared to other forms of psoriasis is HLA-DRB1*1101. On the other hand, HLA-DRB1*0102 was significantly associated with other types of psoriasis.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 3

HLA-DRB1 allele frequency in plaque-type and other types of psoriasis.

From Table 1, HLA-DRB1* 0306 was significantly associated with all types of psoriasis in comparison with control groups, but the allele is not associated with plaque-type or other types of psoriasis when we compare both groups as shown in Table 3.

Discussion

Psoriasis is a disease with multiple etiological factors, both environmental and genetic factors can determine the clinical and susceptibility patterns of the disease.12,13 Part of the genetic predisposition is due to genes within the major histocompatibility complex (MHC).14,15

Studies in different parts of the world have shown that there is an association between Class I and II (MHC) and psoriasis. A Turkish study found that HLA-B*57, Cw6, and DRB1*07 alleles are associated with the disease.7 Human leukocyte antigen-DR13 was found to be significantly associated with plaque psoriasis in an Omani patient.16

This study showed that HLA-DRB1*1101 was significantly associated with plaque-type psoriasis, and DRB1*0102 was significantly associated with other types of psoriasis, while DRB1*0306 was significantly associated with all types of psoriasis. These findings are different from other findings mentioned previously from different parts of the world. Two published Iraqi studies on the association of HLA-DRB1* with vitiligo and alopecia areata, showed that HLA-DRB1*1101 was significantly associated with these diseases.17,18 It has been proposed that there was an association between class II HLA and the occurrence of autoimmune disease.19,20,21 Vitiligo, alopecia areata, and psoriasis are considered autoimmune diseases, this sheds light on the possibility that the HLA-DRB1*1101 allele may be a risk factor for autoimmune diseases in the Iraqi population.

In our study, psoriasis was significantly associated with HLA-DRB1*01 and *03, while the HLA-DRB1*07 allele had no significant association with the disease as compared to a Turkish study,7 although DR*07 allele carriers in patients with psoriasis is 25% compared to the control group, which was 23%. This can be explained by either low sample size or different ethnic groups.

What is well known is that there is an association between psoriasis and HLA especially Cw0602 which is considered as psoriatic risk gene. With the advent of new therapeutic modalities for psoriasis and the introduction of biological therapy for the treatment of psoriasis, several newly published studies showed that there is no association between HLA-Cw06 genetic status and response to treatment especially ustekinumab and Secukinumab.22,23 Other study showed that the presence of HLA-A Bw4-80I could result in reduction in the response to treatment with Etanercept.24 So HLA alleles play an important role in psoriasis pathogenesis with controversial role in response to biological therapy.

The limitations of this study are low sample size and lack of correlation between the severity of the disease and the significant alleles in patients with plaque-type and other types of psoriasis.

In conclusion, HLA-DRB1*0102, *0306 alleles are risky psoriatic genes for all types of psoriasis while HLA-DRB1*1101, *0102 are risk genes in plaque-type and other types of psoriasis. There is a need for more studies to show the effect of these significant alleles to biological therapy response in Iraqi psoriatic patients and to correlate the observations with other studies.

Clinical Practice Guidelines

Clinical Practice Guidelines must include a short abstract. There should be an Introduction section addressing the objective in producing the guideline, what the guideline is about and who will benefit from the guideline. It should describe the population, conditions, health care setting and clinical management/diagnostic test. Authors should adequately describe the methods used to collect and analyze evidence, recommendations and validation. If it is adapted, authors should include the source, how, and why it is adapted? The guidelines should include not more than 50 references, 2-4 illustrations/tables, and an algorithm.

Acknowledgment

We would like to thank Iraqi Research and Development Department, Ministry of Higher Education and Scientific Research for their support. Our thanks to the University of Baghdad and Al-Kindy College of Medicine who facilitated this study. We would like to thank (www.webshop.elsevier.com) for English editing.

Footnotes

  • Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company.

  • Received June 11, 2018.
  • Accepted July 25, 2018.
  • Copyright: © Saudi Medical Journal

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

  1. ↵
    1. Longo D,
    2. Kasper D,
    3. Jameson J,
    4. Fauci A,
    5. Hauser S,
    6. Loscalzo J
    (2012) Harrisons principle of internal medicine (McGraw-Hill, New York (NY)), 18th ed, p 398.
  2. ↵
    1. Walker B,
    2. Colledge N,
    3. Ralston S,
    4. Penman I
    1. Ibbotson S,
    2. Dawe R
    (2014) in Davidson's principles and practice of Medicine, Skin Disease, eds Walker B, Colledge N, Ralston S, Penman I (Churchill Livingstone, Edinburgh (Scots)), p 1286.
  3. ↵
    1. Giffiths C,
    2. Barker J,
    3. Bleiker T,
    4. Chalmers R,
    5. Creamer D
    1. Burden D,
    2. Kirby B
    (2016) in Rook's textbook of dermatology, Psoriasis and related disorders, eds Giffiths C, Barker J, Bleiker T, Chalmers R, Creamer D (Willy Blackwell, London (UK)), p 35.1.
  4. ↵
    1. Krueger JG
    (2015) An autoimmune “attack” on melanocytes triggers soriasis and cellular hyperplasia. J Exp Med 212:2186.
    OpenUrlFREE Full Text
  5. ↵
    1. Ogawa E,
    2. Sato Y,
    3. Minagawa A,
    4. Okuyama R
    (2018) Pathogenesis of psoriasis and development of treatment. J Dermatol 45:264–272.
    OpenUrl
  6. ↵
    1. Chandran V,
    2. Bull SB,
    3. Pellett FJ,
    4. Ayearst R,
    5. Rahman P,
    6. Gladman DD
    (2013) Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Hum Immunol 74:1333–1338.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Okada Y,
    2. Han B,
    3. Tsoi LC,
    4. Stuart PE,
    5. Ellinghaus E,
    6. Tejasvi T,
    7. et al.
    (2014) Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet 95:162–172.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Harden JL,
    2. Krueger JG,
    3. Bowcock AM
    (2015) The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun 64:66–73.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Mahil SK,
    2. Capon F,
    3. Barker JN
    (2016) Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol 38:11–27.
    OpenUrl
  10. ↵
    1. Atasoy M,
    2. Pirim I,
    3. Bayrak OF,
    4. Ozdemir S,
    5. Ikbal M,
    6. Erdem T,
    7. et al.
    (2006) Association of HLA class I and class II alleles with psoriasis vulgaris in Turkish population. Influence of type I and II psoriasis. Saudi Med J 27:373–376.
    OpenUrlPubMed
  11. ↵
    1. Queiro R,
    2. Morante I,
    3. Cabezas I,
    4. Acasuso B
    (2016) HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology (Oxford) 55:221–229.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Barrea L,
    2. Nappi F,
    3. Di Somma C,
    4. Savanelli MC,
    5. Falco A,
    6. Balato A,
    7. et al.
    (2016) Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist. Int J Environ Res Public Health 13:E743.
    OpenUrl
  13. ↵
    1. Enamandram M,
    2. Kimball AB
    (2013) Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol 133:287–289.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Yin X,
    2. Low HQ,
    3. Wang L,
    4. Li Y,
    5. Ellinghaus E,
    6. Han J,
    7. et al.
    (2015) Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat Commun 6:6916.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Shawkatová I,
    2. Javor J,
    3. Párnická Z,
    4. Kozub P,
    5. Zilínková M,
    6. Frey P,
    7. et al.
    (2013) HLA-C, DRB1 and DQB1 alleles involved in genetic predisposition to psoriasis vulgaris in the Slovak population. Folia Microbiol (Praha) 58:319–324.
    OpenUrl
  16. ↵
    1. Al-Mamari F,
    2. Al-Shirawi A,
    3. Banodkar D,
    4. Al-Hashmi S,
    5. Al-Yahyaae F,
    6. Varghese M,
    7. et al.
    (2009) HLA Antigens in Omani Psoriasis Vulgaris Patients. Oman Med J 24:27–29.
    OpenUrlPubMed
  17. ↵
    1. Abdullah GA,
    2. Abbas MY,
    3. Hyam R,
    4. Mahdi BM,
    5. Zalzala HH,
    6. Abid LA,
    7. et al.
    (2015) The association between Human Leukocyte Antigen-DRB1 and vitiligo. European Journal of Medicine 10:190–194.
    OpenUrl
  18. ↵
    1. Abdullah GA,
    2. Abbas MY,
    3. Mahdi BM,
    4. Raouf H,
    5. Zalzala HH,
    6. Abid LA,
    7. et al.
    (2016) Effect of HLA DRB1 on development of alopecia areata. International Journal of Research and Development in Pharmacy and Life Sciences 5:1910–1914.
    OpenUrl
  19. ↵
    1. Tsai S,
    2. Santamaria P
    (2013) MHC Class II Polymorphisms, Autoreactive T-Cells, and Autoimmunity. Front Immunol 4:321.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Matzaraki V,
    2. Kumar V,
    3. Wijmenga C,
    4. Zhernakova A
    (2017) The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol 18:76.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Prinz JC
    (2018) Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis. Front Immunol 9:954.
    OpenUrlCrossRef
  22. ↵
    1. Anzengruber F,
    2. Ghosh A,
    3. Maul JT,
    4. Drach M,
    5. Navarini AA
    (2018) Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis. Psoriasis (Auckl) 8:7–11.
    OpenUrl
  23. ↵
    1. Costanzo A,
    2. Bianchi L,
    3. Flori ML,
    4. Malara G,
    5. Stingeni L,
    6. Bartezaghi M,
    7. et al.
    (Apr 28, 2018) Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol.
  24. ↵
    1. Guarene M,
    2. Pasi A,
    3. Bolcato V,
    4. Cananzi R,
    5. Piccolo A,
    6. Sbarsi I,
    7. et al.
    (2018) The Presence of HLA-A Bw4-80I KIR Ligands Could Predict “Difficult-to-Treat” Psoriasis and Poor Response to Etanercept. Mol Diagn Ther 22:471–474.
    OpenUrl
PreviousNext
Back to top

In this issue

Saudi Medical Journal: 39 (9)
Saudi Medical Journal
Vol. 39, Issue 9
1 Sep 2018
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients
Haider H. Zalzala, Galawish A. Abdullah, Mohammed Y. Abbas, Hyam R. Mohammedsalih, Batool M. Mahdi
Saudi Medical Journal Sep 2018, 39 (9) 886-890; DOI: 10.15537/smj.2018.9.23156

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients
Haider H. Zalzala, Galawish A. Abdullah, Mohammed Y. Abbas, Hyam R. Mohammedsalih, Batool M. Mahdi
Saudi Medical Journal Sep 2018, 39 (9) 886-890; DOI: 10.15537/smj.2018.9.23156
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The risk factors for cardiovascular disease and chronic kidney disease in patients with nonalcoholic fatty liver disease in Saudi Arabia
  • Prolonged flight exposure and its effects on sinonasal health among aircrew members
  • Identifying individuals at risk of post-stroke depression
Show more Original Article

Similar Articles

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire